tildrakizumab
Ilumya (tildrakizumab) is an interleukin-23 inhibitor for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Given by injection at spaced intervals, it calms the IL-23-driven inflammatory loop behind psoriatic plaques.
This page is based on FDA prescribing information and the EMA medicine record for tildrakizumab, cross-checked with DailyMed and the National Cancer Institute dictionary; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
Psoriasis is a fire kept burning by a bellows called IL-23, which pumps immune cells into overdrive in the skin. Tildrakizumab clamps the bellows shut by gripping the p19 piece unique to IL-23. Without the extra air, the inflammatory fire dies down and plaques fade, while related pathways the body still needs are left running.
In simple terms
In plaque psoriasis, the immune system mistakenly keeps skin cells inflamed and multiplying too fast. A signalling protein called IL-23 helps maintain that inflammation. Tildrakizumab is a humanized antibody given by subcutaneous injection that binds the p19 subunit of IL-23, neutralising it and preventing it from engaging its receptor. With the signal blocked, the immune cells that drive plaque formation quiet down, and red scaly plaques clear.
In depth
Tildrakizumab is a humanized monoclonal antibody directed against the p19 protein subunit of interleukin-23. Upon subcutaneous administration it targets and binds the p19 subunit of IL-23, neutralising IL-23 and preventing its binding to the IL-23 receptor. This inhibits IL-23-mediated signalling and the differentiation of CD4-positive T cells into Th1 and Th17 cells, preventing Th1- and Th17-mediated responses and cytokine production. IL-23 is a pro-inflammatory cytokine that plays a key role in immune regulation and is upregulated in immune-mediated inflammatory disorders such as plaque psoriasis.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How tildrakizumab clamps the IL-23 bellows shut in plaque psoriasis
- Tildrakizumab clamps the bellows shut by gripping the p19 piece unique to IL-23.
- Tildrakizumab is a humanized antibody given by subcutaneous injection that binds the p19 subunit of IL-23, neutralising it and preventing it from engaging its receptor.
- Tildrakizumab is a humanized monoclonal antibody directed against the p19 protein subunit of interleukin-23.
- This inhibits IL-23-mediated signalling and the differentiation of CD4-positive T cells into Th1 and Th17 cells, preventing Th1- and Th17-mediated responses and cytokine production.
Target: Interleukin-23 (IL-23, p19 subunit)
A pro-inflammatory cytokine upregulated in immune-mediated inflammatory disorders; blocking its p19 subunit interrupts the Th1/Th17 inflammatory loop that sustains psoriatic plaques.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- For the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Approved uses in European Union
EMA- For the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy
Official sources
The statements on this page trace back to these records.
- Ilumetri (tildrakizumab) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- DailyMed: ILUMYA (tildrakizumab) official US label
U.S. National Library of Medicine, DailyMed
- U.S. Food and Drug Administration: tildrakizumab prescribing information
U.S. Food and Drug Administration
- National Cancer Institute: tildrakizumab
National Cancer Institute
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.